Abstract
The world has been faced with the coronavirus disease 2019 (COVID-19) pandemic. Several antiviral medications have been granted emergency use authorization for treatment of patients with COVID-19 including Paxlovid (nirmatrelvir and ritonavir) and Lagevrio (molnupiravir).1 There are no data on the use of these medications in patients with inflammatory bowel disease (IBD) who develop a COVID-19 infection. This report compares the outcomes of patients with IBD who received antiviral medications for COVID-19 with those who did not and with non-IBD patients who received antiviral medications.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
